Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial

Banu K Arun,Hyo S Han,Bella Kaufman,Hans Wildiers,Michael Friedlander,Jean-Pierre Ayoub,Shannon L Puhalla,Katherine M Bell-McGuinn,Bruce A Bach,Madan G Kundu,Christine K Ratajczak,David Maag,Véronique Diéras

European Journal of Cancer（2021）

引用 8|浏览4

暂无评分

摘要

•BROCADE3 showed veliparib plus platinum efficacy for BRCA+ advanced breast cancer.•This subanalysis was in patients without prior chemotherapy for metastatic disease.•Addition of veliparib to carboplatin–paclitaxel led to durable disease control.•The data suggest a benefit of veliparib plus platinum in early lines of therapy.

查看译文

关键词

PARP inhibitor,Chemotherapy,Breast cancer,BRCA

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要